Atara Biotherap (ATRA)

$13.76 +0.37 (2.76%)
Market Cap 99.21M
Revenue (ttm) 128.94M
Net Income (ttm) -85.40M
EPS (ttm) N/A
PE Ratio 6.14
Forward PE 7.78
Profit Margin -66.23%
Debt to Equity Ratio 0.00
Volume 43,900
Avg Vol 57,928
Day's Range N/A - N/A
Shares Out 7.21M
Stochastic %K 86%
Beta 0.26
Analysts Sell
Price Target $13.33

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Ket...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 623 4211
Address:
1280 Rancho Conejo Blvd, Thousand Oaks, United States
PaulLaurent
PaulLaurent Nov. 16 at 7:56 PM
🚀📈 Top Gainers 📈🚀AH $CWAN $EEIQ $ATRA $QUBT $ATGL
0 · Reply
takingstock73
takingstock73 Nov. 15 at 12:40 PM
$ATRA who hit 15.75 AH?, must be foolery
0 · Reply
Drashkawisha
Drashkawisha Nov. 14 at 12:12 PM
$ATRA The Case: A turnaround/restructuring play. Fact 1: Generates royalty revenue from its approved product (Ebvallo) in Europe. Fact 2: The US value proposition is now tied to the progress of its next-generation allogeneic CAR-T platform (ATA3219).
0 · Reply
Drashkawisha
Drashkawisha Nov. 13 at 6:32 PM
$ATRA what a beautiful place to be
0 · Reply
takingstock73
takingstock73 Nov. 12 at 5:21 PM
$ATRA let's keep the focus on the 70-75% success probability leading to a 40m milestone and lucrative ongoing royalties and not on boiler plate biotech risk factor language. I think everyone knows the risks here.
0 · Reply
d_risk
d_risk Nov. 12 at 4:37 PM
$ATRA - Atara Biotherapeutics, Inc. - 10Q - Updated Risk Factors ATRA’s 10-Q risk factors now highlight strategic alternatives and liquidation risks, ongoing losses despite 2025 net income forecast, early-stage status with no Phase 3 completions or regulatory approvals, explicit going concern doubts, cash shortfall, expanded product development and manufacturing risks, new clinical trial and pandemic disruption risks, sharper focus on regulatory, competitive, and commercialization challenges, new royalty financing and internal controls risks, and added exposure to data privacy, environmental, and tax asset limitations. #Biotechnology #PandemicImpact #RegulatoryChallenges #FinancialRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/ATRA/10-Q/2025-11-12
1 · Reply
Drashkawisha
Drashkawisha Nov. 12 at 3:20 PM
$ATRA ״Under its commercialization agreement with Pierre Fabre Medicament, Atara is eligible to receive a $40 million milestone payment upon FDA approval of the tab-cel BLA. In addition, Atara will be eligible to receive double-digit tiered royalties as a percentage of net sales and milestones related to commercial sales of EBVALLO. We anticipate the full-year 2025 operating expenses will decrease by at least 60% compared to 2024, driven by the transition of substantially all tab-cel activities and associated costs to Pierre Fabre Laboratories as well as the implementation of operational efficiencies in the first half of the year. Atara projects that cash, cash equivalents and short-term investments as of September 30, 2025, combined with the net proceeds of the milestone payment upon tab-cel BLA approval under its commercialization agreement with Pierre Fabre Medicament, will provide significant cash runway and flexibility for the company to execute on its strategic priorities.״
0 · Reply
ballyhooo
ballyhooo Nov. 12 at 2:14 PM
$ATRA *Atara Biotherapeutics: Tab-cel Prescription Drug User Fee Act Target Action Date of Jan 10 >ATRA
0 · Reply
takingstock73
takingstock73 Nov. 12 at 12:59 PM
$ATRA Re: PDUFA: from below link Key Insight: Tabelecleucel is T-cell cell therapy for post-transplant immunocompromised patients. Clinical data show lasting responses in 70%+ patients. Cell therapy is next-gen frontier. Probability of approval estimated 70-75%.
0 · Reply
merlin8121
merlin8121 Nov. 12 at 10:59 AM
$ATRA report at this link https://www.merlintrader.com/pdufa-jan-2026/
0 · Reply
Latest News on ATRA
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Nov 12, 2025, 9:00 AM EST - 4 days ago

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Nov 3, 2025, 9:00 AM EST - 13 days ago

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 7 weeks ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ASMB CORT

Atara Biotherapeutics Announces Changes to Its Board of Directors

Sep 3, 2025, 6:00 PM EDT - 2 months ago

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Aug 11, 2025, 4:01 PM EDT - 3 months ago

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Jul 24, 2025, 8:57 AM EDT - 4 months ago

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 24, 2025, 8:00 AM EDT - 4 months ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Jul 15, 2025, 8:00 AM EDT - 4 months ago

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Jul 14, 2025, 8:00 AM EDT - 4 months ago

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 16, 2025, 8:50 PM EDT - 6 months ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:35 AM EDT - 6 months ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 15, 2025, 8:30 AM EDT - 6 months ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

May 5, 2025, 5:06 PM EDT - 6 months ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 7, 2025, 4:01 PM EST - 9 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 9 months ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 9 months ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 14, 2025, 8:11 AM EST - 9 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 11, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 10 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 9, 2025, 7:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:01 PM EST - 10 months ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 7, 2025, 7:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 6, 2025, 7:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 5, 2025, 7:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 4, 2025, 7:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 11:00 AM EST - 10 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 3, 2025, 7:00 AM EST - 10 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 30, 2025, 7:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 29, 2025, 7:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Jan 28, 2025, 11:00 AM EST - 10 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

Jan 28, 2025, 7:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Jan 28, 2025, 3:23 AM EST - 10 months ago

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

Jan 27, 2025, 8:30 PM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Jan 21, 2025, 1:11 PM EST - 10 months ago

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Jan 21, 2025, 7:30 AM EST - 10 months ago

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Jan 21, 2025, 12:21 AM EST - 10 months ago

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

PaulLaurent
PaulLaurent Nov. 16 at 7:56 PM
🚀📈 Top Gainers 📈🚀AH $CWAN $EEIQ $ATRA $QUBT $ATGL
0 · Reply
takingstock73
takingstock73 Nov. 15 at 12:40 PM
$ATRA who hit 15.75 AH?, must be foolery
0 · Reply
Drashkawisha
Drashkawisha Nov. 14 at 12:12 PM
$ATRA The Case: A turnaround/restructuring play. Fact 1: Generates royalty revenue from its approved product (Ebvallo) in Europe. Fact 2: The US value proposition is now tied to the progress of its next-generation allogeneic CAR-T platform (ATA3219).
0 · Reply
Drashkawisha
Drashkawisha Nov. 13 at 6:32 PM
$ATRA what a beautiful place to be
0 · Reply
takingstock73
takingstock73 Nov. 12 at 5:21 PM
$ATRA let's keep the focus on the 70-75% success probability leading to a 40m milestone and lucrative ongoing royalties and not on boiler plate biotech risk factor language. I think everyone knows the risks here.
0 · Reply
d_risk
d_risk Nov. 12 at 4:37 PM
$ATRA - Atara Biotherapeutics, Inc. - 10Q - Updated Risk Factors ATRA’s 10-Q risk factors now highlight strategic alternatives and liquidation risks, ongoing losses despite 2025 net income forecast, early-stage status with no Phase 3 completions or regulatory approvals, explicit going concern doubts, cash shortfall, expanded product development and manufacturing risks, new clinical trial and pandemic disruption risks, sharper focus on regulatory, competitive, and commercialization challenges, new royalty financing and internal controls risks, and added exposure to data privacy, environmental, and tax asset limitations. #Biotechnology #PandemicImpact #RegulatoryChallenges #FinancialRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/ATRA/10-Q/2025-11-12
1 · Reply
Drashkawisha
Drashkawisha Nov. 12 at 3:20 PM
$ATRA ״Under its commercialization agreement with Pierre Fabre Medicament, Atara is eligible to receive a $40 million milestone payment upon FDA approval of the tab-cel BLA. In addition, Atara will be eligible to receive double-digit tiered royalties as a percentage of net sales and milestones related to commercial sales of EBVALLO. We anticipate the full-year 2025 operating expenses will decrease by at least 60% compared to 2024, driven by the transition of substantially all tab-cel activities and associated costs to Pierre Fabre Laboratories as well as the implementation of operational efficiencies in the first half of the year. Atara projects that cash, cash equivalents and short-term investments as of September 30, 2025, combined with the net proceeds of the milestone payment upon tab-cel BLA approval under its commercialization agreement with Pierre Fabre Medicament, will provide significant cash runway and flexibility for the company to execute on its strategic priorities.״
0 · Reply
ballyhooo
ballyhooo Nov. 12 at 2:14 PM
$ATRA *Atara Biotherapeutics: Tab-cel Prescription Drug User Fee Act Target Action Date of Jan 10 >ATRA
0 · Reply
takingstock73
takingstock73 Nov. 12 at 12:59 PM
$ATRA Re: PDUFA: from below link Key Insight: Tabelecleucel is T-cell cell therapy for post-transplant immunocompromised patients. Clinical data show lasting responses in 70%+ patients. Cell therapy is next-gen frontier. Probability of approval estimated 70-75%.
0 · Reply
merlin8121
merlin8121 Nov. 12 at 10:59 AM
$ATRA report at this link https://www.merlintrader.com/pdufa-jan-2026/
0 · Reply
takingstock73
takingstock73 Nov. 11 at 2:16 PM
$ATRA 60 Days to Jan 10. Just sayin'. I highly doubt PF is going to let 3rd party issue go uncorrected. Buckle up
1 · Reply
Drashkawisha
Drashkawisha Nov. 10 at 2:11 PM
$ATRA The EU approval of Tab-cel proves the drug works. Now it's just about getting the US BLA across the finish line. The operational runway is tight, but the asset is de-risked clinically. Watching closely for the submission announcement catalyst.
0 · Reply
takingstock73
takingstock73 Nov. 6 at 3:30 PM
$ATRA getting back to where we should be
0 · Reply
Drashkawisha
Drashkawisha Nov. 6 at 3:29 PM
$ATRA ok. That’s nice
0 · Reply
Acdrybones
Acdrybones Nov. 6 at 1:52 PM
$ATRA didn’t expect it to go on pre market
0 · Reply
Dimon11
Dimon11 Nov. 5 at 9:45 PM
$ATRA share movement was pretty unexpected for me last few days. I shouldn't have added....
0 · Reply
Dimon11
Dimon11 Nov. 5 at 9:43 PM
$ATRA volume AH???
1 · Reply
jai105
jai105 Nov. 5 at 9:30 PM
$ATRA buying back tomorrow
0 · Reply
Vakeshka
Vakeshka Nov. 5 at 7:39 PM
$ATRA why is the company staying silent on the BLA transfer? That's definitely a material event so a formal PR would be expected, if not required.
2 · Reply
takingstock73
takingstock73 Nov. 5 at 7:21 PM
$ATRA that is not a true statement
1 · Reply
Markus79
Markus79 Nov. 5 at 6:25 PM
$ATRA here is the reason for the drop, atara no longer owns Tabelecleucel: https://finance.yahoo.com/news/pierre-fabre-pharmaceuticals-announces-transfer-140000212.html
0 · Reply
takingstock73
takingstock73 Nov. 5 at 3:53 PM
$ATRA super low volume manipulation
1 · Reply